| $350M | ||
| $172M | ||
| $127M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $275,500 | 1 | 7 |
Sells | $4,806,137 | 13 | 93 |
| Kaplan Myron | director | 1 | $275,500 | 0 | $0 | $275,500 |
| DUNTON ALAN W | director | 0 | $0 | 2 | $391,300 | $-391,300 |
| Lefkowitz Steven W | director | 0 | $0 | 1 | $475,200 | $-475,200 |
| Zelnick Kaufman Beth | Chief Legal Officer | 0 | $0 | 1 | $670,264 | $-670,264 |
| Hurlburt Elizabeth | Chief Operating Officer | 0 | $0 | 2 | $711,817 | $-711,817 |
| Todisco Joseph | Chief Executive Officer | 0 | $0 | 2 | $1.01M | $-1.01M |
| Dillione Janet | director | 0 | $0 | 5 | $1.55M | $-1.55M |
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.
Over the last 12 months, insiders at CorMedix Inc. have bought $275,500 and sold $4.81M worth of CorMedix Inc. stock.
On average, over the past 5 years, insiders at CorMedix Inc. have bought $153,784 and sold $3.19M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Kaplan Myron (director) — $275,500.
The last purchase of 25,000 shares for transaction amount of $275,500 was made by Kaplan Myron (director) on 2025‑10‑23.
| 2026-01-21 | Sale | Dillione Janet | director | 10,000 0.0119% | $6.88 | $68,800 | +4.91% | |
| 2025-12-30 | Sale | DUNTON ALAN W | director | 20,000 0.0264% | $13.00 | $260,000 | -38.54% | |
| 2025-12-18 | Sale | Todisco Joseph | Chief Executive Officer | 30,000 0.0383% | $12.00 | $360,000 | -35.19% | |
| 2025-12-09 | Sale | Lefkowitz Steven W | director | 40,000 0.052% | $11.88 | $475,200 | -33.22% | |
| 2025-12-09 | Sale | Dillione Janet | director | 34,000 0.0446% | $12.00 | $408,000 | -33.22% | |
| 2025-12-02 | Sale | Dillione Janet | director | 46,657 0.0605% | $10.00 | $466,570 | -20.19% | |
| 2025-11-24 | Sale | Dillione Janet | director | 26,343 0.0343% | $9.93 | $261,586 | -20.16% | |
| 2025-11-14 | Sale | Dillione Janet | director | 30,000 0.039% | $11.42 | $342,600 | -30.16% | |
| 2025-10-23 | Kaplan Myron | director | 25,000 0.0326% | $11.02 | $275,500 | -29.89% | ||
| 2025-09-12 | Sale | Todisco Joseph | Chief Executive Officer | 50,000 0.0673% | $13.00 | $650,000 | -36.51% | |
| 2025-09-12 | Sale | DUNTON ALAN W | director | 10,000 0.0136% | $13.13 | $131,300 | -36.51% | |
| 2025-09-11 | Sale | Hurlburt Elizabeth | Chief Operating Officer | 41,121 0.055% | $13.08 | $537,863 | -37.13% | |
| 2025-09-09 | Sale | Zelnick Kaufman Beth | Chief Legal Officer | 50,000 0.0689% | $13.41 | $670,264 | -36.84% | |
| 2025-09-09 | Sale | Hurlburt Elizabeth | Chief Operating Officer | 12,876 0.0179% | $13.51 | $173,955 | -36.84% | |
| 2024-11-14 | Sale | Hurlburt Elizabeth | EVP | 140,027 0.2312% | $11.18 | $1.57M | +1.14% | |
| 2024-10-31 | Mistry Erin | EVP, Chief Commercial Officer | 1,500 0.0026% | $9.99 | $14,985 | +10.39% | ||
| 2024-03-13 | Todisco Joseph | Chief Executive Officer | 13,561 0.024% | $3.74 | $50,718 | +76.54% | ||
| 2023-12-15 | DUNTON ALAN W | director | 3,000 0.0055% | $3.30 | $9,900 | +52.11% | ||
| 2023-12-14 | DUNTON ALAN W | director | 3,000 0.0055% | $3.45 | $10,350 | +45.51% | ||
| 2023-11-17 | Mistry Erin | Chief Commercial Officer | 1,000 0.0018% | $4.00 | $4,000 | +17.46% |
| Todisco Joseph | Chief Executive Officer | 509496 0.6494% | $4.3M | 6 | 2 | +16.79% |
| Kaplan Myron | director | 201034 0.2563% | $1.69M | 18 | 0 | +9.53% |
| Zelnick Kaufman Beth | Chief Legal Officer | 180418 0.23% | $1.52M | 0 | 1 | |
| Hurlburt Elizabeth | Chief Operating Officer | 176990 0.2256% | $1.49M | 0 | 4 | |
| Lefkowitz Steven W | director | 80498 0.1026% | $678,598.14 | 7 | 7 | +58.05% |
| DUNTON ALAN W | director | 40250 0.0513% | $339,307.50 | 4 | 2 | +43.21% |
| Dillione Janet | director | 38473 0.049% | $324,327.39 | 9 | 5 | <0.0001% |
| Gelbfish Gary A. | director | 2101121 2.6782% | $17.71M | 2 | 0 | <0.0001% |
| PHARMABIO DEVELOPMENT INC | 10 percent owner | 778563 0.9924% | $6.56M | 0 | 1 | |
| TELLEZ CORA M | director | 182371 0.2325% | $1.54M | 15 | 0 | <0.0001% |
| Khan Mehmood | director | 178767 0.2279% | $1.51M | 10 | 0 | +14.81% |
| ELLISON RUSSELL H | director | 160000 0.2039% | $1.35M | 1 | 0 | |
| ARMSTRONG JR. JOHN L. | Exec VP of Tech Operations | 96878 0.1235% | $816,681.54 | 5 | 0 | +5.98% |
| Baluch Khoso | Chief Executive Officer | 60905 0.0776% | $513,429.15 | 9 | 0 | +19.59% |
| MILBY RANDY | Chief Executive Officer | 57026 0.0727% | $480,729.18 | 20 | 0 | +32.67% |
| Houser Mark T. | Chief Medical Officer | 52832 0.0673% | $445,373.76 | 2 | 0 | |
| Mistry Erin | EVP, Chief Commercial Officer | 52011 0.0663% | $438,452.73 | 2 | 0 | +13.92% |
| Lefkowitz James | director | 40272 0.0513% | $339,492.96 | 1 | 0 | |
| Markvicka Taunia | director | 37100 0.0473% | $312,753.00 | 3 | 0 | <0.0001% |
| Duffy Matthew | director | 28571 0.0364% | $240,853.53 | 0 | 2 | |
| Cook Robert W. | Chief Financial Officer | 27517 0.0351% | $231,968.31 | 6 | 0 | <0.0001% |
| Houghton John C. | President and CEO | 17328 0.0221% | $146,075.04 | 2 | 0 | |
| LENZ BRIAN | CFO, TREASURER & SECRETARY | 17000 0.0217% | $143,310.00 | 3 | 0 | |
| Stewart Robert A | director | 11000 0.014% | $92,730.00 | 1 | 0 | <0.0001% |
| GEORGE MICHAEL W | director | 10000 0.0127% | $84,300.00 | 3 | 0 | <0.0001% |
| Costa Paulo F | director | 10000 0.0127% | $84,300.00 | 1 | 0 | <0.0001% |
| HOFER TIMOTHY M | director | 8425 0.0107% | $71,022.75 | 1 | 0 | |
| Mounts Phoebe | General Counsel | 7200 0.0092% | $60,696.00 | 3 | 0 | +69.23% |
| David Matthew T | Interim CEO and CFO | 3150 0.004% | $26,554.50 | 3 | 0 | +83.5% |
| Pfaffle Antony | Chief Scientific Officer | 0 0% | $0 | 1 | 19 |
CorMedix Inc. (CRMD) | $3,611,891 | 113 | 13.40% | $661.35M |
$9,654,532 | 101 | -5.65% | $649.88M | |
$5,911,307 | 70 | -1.38% | $720.56M | |
$11,663,618 | 57 | 32.07% | $689.14M | |
$24,384,691 | 42 | -30.27% | $665.1M | |
$8,866,498 | 28 | 33.64% | $666.13M | |
$22,020,194 | 25 | 38.25% | $725.31M | |
$129,396,927 | 18 | 48.82% | $668.28M | |
$133,809,976 | 13 | 31.29% | $605.85M | |
$6,385,840 | 12 | 0.69% | $627.73M | |
$57,263,116 | 11 | -8.37% | $679.96M | |
$130,748,265 | 10 | 53.98% | $613.63M | |
$75,069,528 | 10 | 19.77% | $675.87M | |
$13,043,783 | 8 | 732.82% | $565.8M | |
$62,616,785 | 8 | -7.00% | $580.23M | |
$272,024 | 7 | 16.80% | $733.03M | |
$4,745,999 | 5 | -4.91% | $591.84M | |
$2,720,023 | 3 | -11.76% | $609.97M | |
$7,234,370 | 3 | -3.34% | $637.73M |
| Increased Positions | 118 | +59.3% | 11M | +24.35% |
| Decreased Positions | 86 | -43.22% | 12M | -27.88% |
| New Positions | 39 | New | 2M | New |
| Sold Out Positions | 30 | Sold Out | 3M | Sold Out |
| Total Postitions | 231 | +16.08% | 42M | -3.53% |
| Blackrock, Inc. | $69,170.00 | 7.2% | 5.69M | +328,474 | +6.13% | 2025-09-30 |
| Vanguard Group Inc | $48,368.00 | 5.04% | 3.98M | -347,887 | -8.04% | 2025-09-30 |
| Marshall Wace, Llp | $42,238.00 | 4.4% | 3.47M | +893,518 | +34.63% | 2025-09-30 |
| Deerfield Management Company, L.P. | $40,418.00 | 4.21% | 3.32M | +3M | New | 2025-09-30 |
| State Street Corp | $22,321.00 | 2.32% | 1.84M | +233,973 | +14.61% | 2025-09-30 |
| Geode Capital Management, Llc | $22,007.00 | 2.29% | 1.81M | +213,450 | +13.37% | 2025-09-30 |
| Citadel Advisors Llc | $20,880.00 | 2.17% | 1.72M | +2,872 | +0.17% | 2025-09-30 |
| Alyeska Investment Group, L.P. | $15,358.00 | 1.6% | 1.26M | +512,979 | +68.4% | 2025-09-30 |
| Ubs Group Ag | $13,265.00 | 1.38% | 1.09M | +814,964 | +295.34% | 2025-09-30 |
| Morgan Stanley | $10,258.00 | 1.07% | 843,571 | +76,318 | +9.95% | 2025-09-30 |